SLC17A6 (Solute Carrier Family 17 Member 6), also known as VGLUT2 (Vesicular Glutamate Transporter 2), is a critical vesicular glutamate transporter responsible for packaging glutamate into synaptic vesicles at excitatory synapses. This gene is essential for normal glutamatergic neurotransmission in the central nervous system and has been implicated in various neurological and neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis .
| SLC17A6 — Vesicular Glutamate Transporter 2 |
|---|
| Gene Symbol | SLC17A6 |
| Protein Name | VGLUT2 |
| Full Name | Solute Carrier Family 17 Member 6 |
| Chromosome | 11q14.1 |
| NCBI Gene ID | [57084](https://www.ncbi.nlm.nih.gov/gene/57084) |
| OMIM | [607234](https://www.omim.org/entry/607234) |
| Ensembl ID | [ENSG00000164690](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164690) |
| UniProt ID | [Q9P2U7](https://www.uniprot.org/uniprot/Q9P2U7) |
| Protein Length | 582 amino acids |
| Molecular Weight | ~64 kDa |
| Associated Diseases | AD, PD, ALS, Schizophrenia, Depression |
¶ Gene and Protein Structure
The SLC17A6 gene is located on chromosome 11q14.1 and spans approximately 20 kb. It contains 16 exons that encode the VGLUT2 protein. The gene shows conserved synteny across mammals, reflecting its essential role in neuronal function [@moechar2006].
VGLUT2 is a member of the major facilitator superfamily of transporters and contains 12 transmembrane domains arranged in a typical 6+6 topology :
- N-terminal cytosolic domain: Contains targeting signals for synaptic vesicle localization
- Transmembrane domain 1-6: First half of the transporter
- Central loop (Loop 3-4): Large cytoplasmic loop containing regulatory sites
- Transmembrane domain 7-12: Second half of the transporter
- C-terminal cytosolic tail: Contains sorting motifs for vesicular localization
Key functional residues in VGLUT2 include:
- Substrate binding site: Located within the transmembrane domains
- Proton coupling sites: Essential for the proton-dependent transport mechanism
- Vesicle targeting motifs: Tyrosine-based and dileucine motifs in C-terminus
VGLUT2 packages L-glutamate into synaptic vesicles with high affinity and capacity :
- Affinity: Km ~1-2 mM for glutamate
- Capacity: Can accumulate glutamate to concentrations >100 mM in vesicles
- Coupling: Proton-dependent antiport mechanism
- Driving force: Vacuolar H+-ATPase establishes the proton gradient
The transport cycle involves:
- Proton gradient-dependent binding of glutamate
- Conformational change translocating glutamate into the vesicle lumen
- Release of glutamate with proton counter-transport
- Recycling of the transporter to the vesicle membrane
VGLUT2 is essential for maintaining quantal size and excitatory synaptic transmission [@wojcik2004]:
- Quantal content: Each vesicle contains ~1-3 million glutamate molecules
- Release probability: VGLUT2 expression level correlates with release probability
- Synaptic efficacy: Proper glutamate packaging is critical for synaptic strength
- Vesicle cycling: VGLUT2 cycles with synaptic vesicles during exocytosis/endocytosis
VGLUT2 exhibits a distinct expression pattern that complements VGLUT1 in the brain :
High expression regions:
- Thalamus (all nuclei)
- Hypothalamus
- Brainstem (sensory and motor nuclei)
- Deep cerebellar nuclei
- Spinal cord (dorsal horn)
- Substantia nigra (pars reticulata)
- Locus coeruleus
Moderate expression:
- Hippocampus (CA3 region, mossy fibers)
- Cerebral cortex (layer 4-6)
- Basal ganglia (striatum, globus pallidus)
VGLUT2 is expressed in specific neuronal populations:
- Excitatory projection neurons: Thalamocortical, corticostriatal, ponto cerebellar
- Sensory neurons: Trigeminal, spinal dorsal horn
- Neuroendocrine cells: Hypothalamic neurosecretory neurons
- Modulatory neurons: Serotonergic and dopaminergic terminals (co-release)
VGLUT2 shows developmental regulation:
- Embryonic expression: First detected at E14 in mouse brain
- Postnatal increase: Peaks around P14-P21
- Adult pattern: Maintains high expression in thalamus and brainstem
- VGLUT1 compensation: Some VGLUT2-expressing neurons switch to VGLUT1 in adulthood
The vesicular glutamate transporter family includes three paralogs with distinct expression patterns and functions:
| Feature |
VGLUT1 (SLC17A7) |
VGLUT2 (SLC17A6) |
VGLUT3 (SLC17A8) |
| Primary expression |
Cortex, hippocampus |
Thalamus, brainstem |
Subset of cholinergic, serotonergic |
| Synaptic role |
Major forebrain excitatory |
Sensory/motor pathways |
Neuromodulator co-release |
| Disease association |
AD, schizophrenia |
PD, ALS, epilepsy |
Depression, anxiety |
| Knockout phenotype |
Viable, learning deficits |
Neonatal lethal |
Viable, behavioral changes |
VGLUT2 and VGLUT1 show partial redundancy in some brain regions, with VGLUT1 compensating for VGLUT2 loss in certain paradigms [7].
VGLUT2 dysfunction is implicated in Alzheimer's disease pathogenesis through multiple mechanisms :
Synaptic dysfunction:
- VGLUT2 expression is significantly reduced in AD hippocampus and cortex
- This reduction correlates with cognitive decline and amyloid burden
- Loss of VGLUT2 precedes detectable memory impairment in mouse models
Excitatory-inhibitory imbalance:
- Reduced VGLUT2 leads to decreased glutamatergic transmission
- This may contribute to network hyperexcitability observed in early AD
- Compensation by VGLUT1 is insufficient to maintain normal transmission
Amyloid interaction:
- Aβ oligomers directly downregulate VGLUT2 expression
- This effect is mediated through NMDA receptor signaling
- Restoring VGLUT2 rescues synaptic function in animal models
Therapeutic implications:
- VGLUT2 enhancers could restore excitatory transmission
- Gene therapy approaches using AAV-VGLUT2 are in development
- Small molecule potentiators of VGLUT2 are being screened
VGLUT2 plays a critical role in Parkinson's disease pathophysiology :
Dopaminergic-glutamatergic interaction:
- VGLUT2 is expressed in a subset of dopaminergic neurons
- These neurons co-release glutamate and dopamine
- This co-transmission is altered in PD models
Basal ganglia dysfunction:
- VGLUT2 expression in striatum is reduced in PD
- This contributes to altered indirect pathway activity
- Motor symptoms correlate with VGLUT2 deficits
Alpha-synuclein effects:
- α-Synuclein aggregation downregulates VGLUT2
- This effect occurs early in PD progression
- VGLUT2 loss may contribute to synaptic failure
Levodopa-induced dyskinesia:
- Altered VGLUT2 expression in dyskinesia models
- Targeting VGLUT2 reduces dyskinesia severity
- VGLUT2 modulators may improve dopaminergic therapy
VGLUT2 is implicated in ALS pathogenesis :
Motor neuron vulnerability:
- VGLUT2 expression is reduced in ALS motor cortex
- This may contribute to excitability deficits
- VGLUT2 loss correlates with disease progression
Excitotoxicity:
- Dysregulated glutamate release contributes to excitotoxicity
- VGLUT2-mediated glutamate release may be excessive in ALS
- Anti-glutamatergic therapies have shown benefit in some trials
Non-cell autonomous toxicity:
- Astrocytic VGLUT2 may affect motor neuron survival
- Microglial VGLUT2 contributes to neuroinflammation
VGLUT2 alterations are observed in epileptic tissue:
- Increased VGLUT2 expression in seizure foci
- Contributes to hyperexcitability
- VGLUT2 inhibitors have anti-convulsant potential
VGLUT2 dysfunction contributes to schizophrenia pathophysiology :
- Reduced VGLUT2 in prefrontal cortex
- Alters glutamatergic signaling in working memory circuits
- Risk variants in SLC17A6 associated with schizophrenia
¶ Depression and Anxiety
VGLUT2 in mood disorders:
- VGLUT2 expression altered in depression models
- Anxiolytic effects of VGLUT2 modulation
- VGLUT2 in stress response circuits
VGLUT2 in reward circuits :
- VGLUT2 in mesolimbic dopamine pathways
- Altered expression during cocaine self-administration
- Targeting VGLUT2 reduces drug-seeking behavior
VGLUT2 in pain pathways :
- Primary afferent pain fibers express VGLUT2
- VGLUT2 mediates glutamate release in pain transmission
- VGLUT2 antagonists have analgesic potential
Enhancers: Increasing VGLUT2 activity
- Small molecules that potentiate glutamate uptake
- Positive allosteric modulators of VGLUT2
- Gene therapy for overexpression
Inhibitors: Reducing excessive glutamate release
- Used in epilepsy and excitotoxicity
- Competitive antagonists
- Substrate analogs
Gene Therapy:
- AAV-mediated VGLUT2 delivery
- CRISPR-based editing of risk variants
- Viral vector targeting to specific circuits
VGLUT2 as a biomarker:
- CSF VGLUT2 levels correlate with synaptic integrity
- PET ligands for VGLUT2 are in development
- Peripheral blood VGLUT2 mRNA as biomarker
VGLUT2 interacts with multiple synaptic proteins:
| Partner |
Interaction |
Function |
| Synaptophysin |
Direct binding |
Vesicle targeting |
| Synaptotagmin |
Calcium sensing |
Release regulation |
| Clathrin |
Endocytosis |
Vesicle recycling |
| Rab proteins |
Vesicle trafficking |
Localization |
VGLUT2 is regulated by:
- Activity-dependent pathways: Calcium/calmodulin signaling
- Metabolic signals: Glucose and ATP levels
- Hormonal regulation: Thyroid hormone, glucocorticoids
- VGLUT2 global knockout: Neonatal lethality due to respiratory failure
- Conditional knockout: Allows region-specific deletion
- Haploinsufficient mice: Viable with behavioral and cognitive deficits
- VGLUT2-eGFP reporters: Visualize VGLUT2-expressing neurons
- Humanized mouse models: Express human SLC17A6 variants
- Disease models: VGLUT2 changes in AD/PD transgenic mice
- Electrophysiology:Measuring glutamatergic transmission
- Immunohistochemistry: Mapping VGLUT2 expression
- Molecular biology: Variant analysis and functional studies
- Live imaging: Vesicle dynamics in real-time